Market Report Summary
- Market – Sickle Cell Disease Treatment Market
- Market Value – US$ 584.0 Mn in 2025
- Market CAGR Value – 6% in 2025
- Market Forecast Year – 2020 to 2030
For Full Information -> Click Here
Read Full Press Release Below
Global sickle cell disease treatment market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by increasing adoption of therapies, growing awareness regarding the sickle cell disease treatment in MEA region. “Sickle Cell Disease Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)” is the new report published by Persistence Market Research for the projected period of 8-years, i.e. 2017-2025.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/16099
- AstraZeneca Plc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Novartis AG
- Pfizer Inc.
- Baxter International Inc.
- Emmaus Life Sciences, Inc.
- Bluebird bio, Inc.
- Global Blood Therapeutics Inc.
- Sangamo Therapeutics, Inc.
- Acceleron Pharma, Inc.
- Arena Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
Global Sickle Cell Disease Treatment Market: Drivers
- Increasing discretionary research funding for Sickle cell anaemia in developed countries
- Governments focus on creating awareness on sickle cell anemia cure
- Aging population in developed economies and rising affluence in emerging markets to boost healthcare spending
- Demand for drug therapy in combination with surgeries and blood transfusion
- Changes in lifestyle to increase the probability of genomic mutations
- Increasing penetration of FDA approved drugs in the market
- Various key players in the sickle cell disease treatment market are signing partnerships and licensing deals to share the research and development platform
- Reduction of overall diagnosis cost for sickle cell diseases
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/16099
Global Sickle Cell Disease Treatment Market: Forecast by Drug Type
On the basis of drug type, the global sickle cell disease treatment market is segmented into hydroxyurea, antibiotics, pain-relieving medications, and Others.
The hydroxyurea segment is likely to be accounted for 38.7 % market revenue share in 2017, which is expected to increase to 35.7% by 2025 end. This drug type is expected to account for a high revenue contribution in the global sickle cell disease treatment market as compared to other drug types over the forecast period.
Hydroxyurea product is expected to be the second attractive drug type segment in sickle cell disease treatment market, with market attractiveness index of 1.2.
Global Sickle Cell Disease Treatment Market: Forecast by Disease Type
On the basis of disease type, the global sickle cell disease treatment market is segmented into sickle cell anemia, sickle hemoglobin C disease, and sickle beta thalassemia. Sickle cell anemia is expected to be the most lucrative among all disease type segment of sickle cell disease treatment market, with attractiveness index of 1.8.
Sickle Beta Thalassemia is expected to be the second attractive drug type segment in sickle cell disease treatment market, with market attractiveness index of 0.7.
Global Sickle Cell Disease Treatment Market: Forecast by Distribution Channel
This segment include hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of drugs by governments to ensure availability in hospital pharmacies.
Hospital pharmacies is expected to be the most lucrative among all distribution channels of sickle cell disease treatment market, with attractiveness index of 2.5. Retail pharmacies is expected to be the second largest distribution channels of sickle cell disease treatment market, with market attractiveness index of 0.4
Access Full Report @ https://www.persistencemarketresearch.com/checkout/16099
Global Sickle Cell Disease Treatment Market: Forecast by Region
Five regions such as North America, Latin America, Europe, APAC and MEA are covered in this report. MEA regions are pegged to represent the most lucrative markets, owing to the high prevalent cases of sickle cell diseases.
The MEA sickle cell disease treatment market is expected to expand at a CAGR of 6.1 % in terms of value over the forecast period. Growing awareness and adoption of treatment for sickle cell disease in India and in the APAC region is expected to create a sizeable opportunity for the players in this market.
Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – email@example.com
Website – https://www.persistencemarketresearch.com